Evaluation Of Preclinical And Clinical Evidence Of Milk Thistle For Chronic Hepatitis C ( Chc )
1264 WordsAug 25, 20156 Pages
Evaluation of preclinical and clinical evidence of milk thistle for chronic hepatitis C (CHC)
Milk thistle is characterized by its dark green leaves and purple flowers with achenes. Products in Australia claimed to be effective for liver conditions. The mechanism of hepatic protection are multi-factorial. Conflicting evidences are found for the beneficial effects of oral preparations on CHC patient while bias exists in the IV trials. Milk thistle has good safety profile. Further studies are required to consolidate the use of intravenous silymarin (Word count:1498).
The aim of this report is to evaluate the preclinical and clinical evidence of milk thistle for CHC. Journal articles (from without impact factor to…show more content…
Silibinin is the main constituent of silymarin.
Identification of herbal extracts includes:
• Comparison with the current scientific literature;
• or Chromatographic comparison against an authenticated specimen;
• or Chromatographic comparison against an extract
Identifying the herbal material uses herbal material monographs in British pharmacopoeia. Guideline on herbal extracts is available in “Guidance on Equivalence of Herbal Extracts in Complementary Medicines” to clarify the quality standards (TGA, 2015).
Good Manufacture Practice regulates the manufacture including storage, production, documentation, sampling and quality control to ensure the quality of product (TGA, 2009).
Mechanisms of action contributed to hepatoprotective effect
Silibinin acts as a competitive inhibitor to stop toxins from binding and uptake by hepatocytes. Increased bile flow flushes toxins out thus reducing enterohepatic recirculation (Braun & Cohen, 2005).
It involved direct elimination of